Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011897:Random Allocation
D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D001224:Aspartic Acid; C013195:sparfosic acid; C018627:1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea; D010746:Phosphonoacetic Acid